Hong Kong and global innovators in genomics and precision medicine.
Natera is scheduled to release its Q2 2026 financial results after the market closes on August 6, 2026. This is a recurring, significant event, and its importance is estimated as High based on substantial market reactions to past earnings reports scheduled.
Caris Life Sciences will report its second quarter 2026 financial results on August 5, 2026; medium importance estimated for standard earnings impact, scheduled.
Q2 2026 earnings release after market close. High importance estimated based on typical market impact of earnings reports, scheduled.
Mike Sullivan's appointment as Chief Commercial Officer becomes effective on July 20, 2026, scheduled.
Announced the offering of in-house PTEN immunohistochemistry (IHC) testing for metastatic prostate cancer on July 14, 2026; medium importance estimated for product line expansion, expected.
A Munich court ruled on July 14, 2026, that Illumina infringed on a patent from Element Biosciences related to DNA sequencing technology.